FDA Grants Approval for Methylphenidate Hydrochloride ANDA206932
The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Methylphenidate Hydrochloride submitted by ABHAI LLC.
Published: July 25, 2026
Updated: July 25, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / ADHD
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
FDA
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of ABHAI LLC's generic Methylphenidate Hydrochloride introduces significant competition in the ADHD market. This could impact pricing and market share for existing branded products, necessitating strategic adjustments.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies of ABHAI LLC's Methylphenidate Hydrochloride product.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.